Azathioprine in liver transplantation: A reevaluation of its use and a comparison with mycophenolate mofetil

American Journal of Transplantation

Volumn 9, Issue 8, 2009, Pages 1725-1731

  Germani, G ^a   Pleguezuelo, M ^a   Villamil, F ^b   Vaghjiani, S ^a   Tsochatzis, E ^a   Andreana, L ^a   Burroughs, A K ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b HOSPITAL UNIVERSITARIO FUNDACIÓN FAVALORO   (Argentina)

Author keywords

Azathioprine; Hepatitis C recurrence; Immunosuppression; Liver transplantation; Mycophenolate mofetil; Rejection; Renal dysfunction

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; STEROID;

ACUTE GRAFT REJECTION; ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; DISEASE SEVERITY; EVALUATION RESEARCH; GASTROINTESTINAL SYMPTOM; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LEUKOPENIA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; NEPHROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SURVIVAL RATE; THROMBOCYTOPENIA;

AZATHIOPRINE; GRAFT REJECTION; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; LIVER TRANSPLANTATION; MYCOPHENOLIC ACID;

EID: 67650938464     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2009.02705.x     Document Type: Article

References (43)

1. McDonald JWD BA, Feagan BG. Evidence-Based Gastroenterology and Hepatology, 2nd Ed. Oxford, UK : Wiley, 1999.
2. Mueller XM. Drug immunosuppression therapy for adult heart transplantation. Part 1: Immune response to allograft and mechanism of action of immunosuppressants. Ann Thorac Surg 2004 77 : 354 362.
3. Fulton B, Markham A. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs 1996 51 : 278 298.
4. Sterneck M, Fischer L, Gahlemann C, Gundlach M, Rogiers X, Broelsch C. Mycophenolate mofetil for prevention of liver allograft rejection: Initial results of a controlled clinical trial. Ann Transplant 2000 5 : 43 46.
5. Wiesner R, Rabkin J, Klintmalm G et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001 7 : 442 450.
6. Fischer L, Sterneck M, Gahlemann CG, Malago M, Rogiers X, Broelsch CE. A prospective study comparing safety and efficacy of mycophenolate mofetil versus azathioprine in primary liver transplant recipients. Transplant Proc 2000 32 : 2125 2127.
7. Schlitt HJ, Barkmann A, Boker KH et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: A randomised controlled study. Lancet 2001 357 : 587 591.
8. Stewart SF, Hudson M, Talbot D, Manas D, Day CP. Mycophenolate mofetil monotherapy in liver transplantation. Lancet 2001 357 : 609 610.
9. Reich DJ, Clavien PA, Hodge EE. Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: Randomized, prospective, multicenter pilot study results. Transplantation 2005 80 : 18 25.
10. Beckebaum S, Cicinnati VR, Klein CG et al. Impact of combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy on renal function, cardiovascular risk factors, and graft function in liver transplant patients: Preliminary results of an open prospective study. Transplant Proc 2004 36 : 2671 2674.
11. Pageaux GP, Rostaing L, Calmus Y et al. Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Liver Transpl 2006 12 : 1755 1760.
12. Sandborn WJ, Hay JE, Porayko MK et al. Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection. Hepatology 1994 19 : 925 932.
13. Chan CY, DasGupta K, Baker AL. Cyclosporin A: Drug discontinuation for the management of long-term toxicity after liver transplantation. Hepatology 1996 24 : 1085 1089.
14. Hong M, Angus PW, Jones RM, Vaughan RB, Gow PJ. Predictors of improvement in renal function after calcineurin inhibitor withdrawal for post-liver transplant renal dysfunction. Clin Transplant 2005 19 : 193 198.
15. Koch RO, Graziadei IW, Schulz F et al. Long-term efficacy and safety of mycophenolate mofetil in liver transplant recipients with calcineurin inhibitor-induced renal dysfunction. Transpl Int 2004 17 : 518 524.
16. Firpi RJ, Nelson DR, Davis GL. Lack of antiviral effect of a short course of mycophenolate mofetil in patients with chronic hepatitis C virus infection. Liver Transpl 2003 9 : 57 61.
17. Zekry A, Gleeson M, Guney S, McCaughan GW. A prospective cross-over study comparing the effect of mycophenolate versus azathioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infection. Liver Transpl 2004 10 : 52 57.
18. Samonakis DN, Triantos CK, Thalheimer U et al. Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transpl 2005 11 : 386 395.
19. Berenguer M, Prieto M, San Juan F et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002 36 : 202 210.
20. Baiocchi L, Angelico M, Petrolati A et al. Correlation between liver fibrosis and inflammation in patients transplanted for HCV liver disease. Am J Transplant 2008 8 : 673 678.
21. Singh N, Gayowski T, Ndimbie OK, Nedjar S, Wagener MM, Yu VL. Recurrent hepatitis C virus hepatitis in liver transplant recipients receiving tacrolimus: Association with rejection and increased immunosuppression after transplantation. Surgery 1996 119 : 452 456.
22. Hunt J, Gordon FD, Lewis WD et al. Histological recurrence and progression of hepatitis C after orthotopic liver transplantation: Influence of immunosuppressive regimens. Liver Transpl 2001 7 : 1056 1063.
23. Berenguer M, Crippin J, Gish R et al. A model to predict severe HCV-related disease following liver transplantation. Hepatology 2003 38 : 34 41.
24. Belli LS, Burroughs AK, Burra P et al. Liver transplantation for HCV cirrhosis: Improved survival in recent years and increased severity of recurrent disease in female recipients: Results of a long term retrospective study. Liver Transpl 2007 13 : 733 740.
25. Eid AJ, Brown RA, Paya CV, Razonable RR. Association between toll-like receptor polymorphisms and the outcome of liver transplantation for chronic hepatitis C virus. Transplantation 2007 84 : 511 516.
26. Walter T, Dumortier J, Guillaud O et al. Rejection under alpha interferon therapy in liver transplant recipients. Am J Transplant 2007 7 : 177 184.
27. Klintmalm GB, Washburn WK, Rudich SM et al. Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transpl 2007 13 : 1521 1531.
28. Langrehr JM, Neumann UP, Lang M et al. First results from a prospective randomized trial comparing steroid-free induction therapy with tacrolimus and MMF versus tacrolimus and steroids in patients after liver transplantation for HCV. Transplant Proc 2002 34 : 1565 1566.
29. Smallwood GA, Davis L, Martinez E, Stieber AC, Heffron TG. Mycophenolate's influence in the treatment of recurrent hepatitis c following liver transplantation. Transplant Proc 2002 34 : 1559 1560.
30. Jain A, Kashyap R, Demetris AJ, Eghstesad B, Pokharna R, Fung JJ. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl 2002 8 : 40 46.
31. Bahra M, Neumann UI, Jacob D et al. MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: Impact on histological course. Am J Transplant 2005 5 : 406 411.
32. Bahra M, Neumann UP, Harren M et al. Significance of mycophenolate mofetil treatment in patients with HCV reinfection after liver transplantation: Impact on clinical course and histologic damage. Transplant Proc 2002 34 : 2934 2935.
33. Sanchez-Bueno F, Ortiz ML, Bermejo J et al. Prognostic factors for hepatitis C recurrence in patients undergoing orthotopic liver transplantation. Transpl Immunol 2006 17 : 47 50.
34. Kornberg A, Kupper B, Tannapfel A, Hommann M, Scheele J. Impact of mycophenolate mofetil versus azathioprine on early recurrence of hepatitis C after liver transplantation. Int Immunopharmacol 2005 5 : 107 115.
35. Kornberg A, Kupper B, Wilberg J et al. Conversion to mycophenolate mofetil for modulating recurrent hepatitis C in liver transplant recipients. Transpl Infect Dis 2007 9 : 295 301.
36. Burak KW, Kremers WK, Batts KP et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002 8 : 362 369.
37. Berenguer M, Prieto M, Rayon JM et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000 32 (4 Pt 1 852 858.
38. Fasola CG, Netto GJ, Jennings LW et al. Recurrence of hepatitis C in liver transplant recipients treated with mycophenolate mofetil. Transplant Proc 2002 34 : 1563 1564.
39. Cholongitas E, Senzolo M, Standish R et al. A systematic review of the quality of liver biopsy specimens. Am J Clin Pathol 2006 125 : 710 721.
40. Gedaly R, Clifford TM, McHugh PP, Jeon H, Johnston TD, Ranjan D. Prevalent immunosuppressive strategies in liver transplantation for hepatitis C: Results of a multi-center international survey. Transpl Int 2008 21 : 867 872.
41. Monthly Index of Medical Specialities 2008. Available from : http://www.mims.co.uk. Accessed 12/01/2008.
42. Wiesner RH, Demetris AJ, Belle SH et al. Acute hepatic allograft rejection: Incidence, risk factors, and impact on outcome. Hepatology 1998 28 : 638 645.
43. Hubscher S. Diagnosis and grading of liver allograft rejection: A European perspective. Transplant Proc 1996 28 : 504 507.